Phase 1, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of XEN901 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 07 Dec 2019
Price : $35 *
At a glance
- Drugs XEN 901 (Primary)
- Indications Epilepsy
- Focus Adverse reactions; First in man
- Sponsors Xenon Pharmaceuticals
- 07 Dec 2019 According to an Xenon Pharmaceuticals media release, update from this study will be presented at the 2019 American Epilepsy Society (AES) Annual Meeting.
- 05 Jun 2019 Results presented in a Xenon Pharmaceuticals media release.
- 05 Jun 2019 Status changed from recruiting to completed, according to a Xenon Pharmaceuticals media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History